CD19 and leukemia: Consequently, bispecific CAR-iNKT cells targeting CD19 and CD133 exhibit superior antileukemic activity compared with conventional CAR T cells in preclinical models of KMT2A-rearranged leukemia, prompting clinical development of this class of product.